UA95828C2 - Твердая рецептура, которая содержит алоглиптин и пиоглитазон - Google Patents

Твердая рецептура, которая содержит алоглиптин и пиоглитазон

Info

Publication number: UA95828C2
Authority: UA; Ukraine
Prior art keywords: pioglitazone; solid preparation; alogliptin; sugar; excipient
Prior art date: 2007-02-01

Application number

UAA200909031A

Other languages

English (en)

Ukrainian (uk)

Inventor

Кенджай Накамура

Кеничиро Кийошима

Юния Номура

Original Assignee

Такеда Фармасьютикал Компани Лимитед

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-01

Filing date

2008-01-30

Publication date

2011-09-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95828(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-30 Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед

2011-09-12 Publication of UA95828C2 publication Critical patent/UA95828C2/ru

Links

238000002360 preparation method Methods 0.000 title abstract 3
239000007787 solid Substances 0.000 title abstract 3
LNTORSITGSWVNQ-DYYGGQLPSA-N 2-[[6-[(3r)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile;5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1.C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 LNTORSITGSWVNQ-DYYGGQLPSA-N 0.000 title 1
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
238000004090 dissolution Methods 0.000 abstract 2
239000000546 pharmaceutical excipient Substances 0.000 abstract 2
229960005095 pioglitazone Drugs 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
150000005846 sugar alcohols Chemical class 0.000 abstract 2
206010012601 diabetes mellitus Diseases 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
229940126585 therapeutic drug Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UAA200909031A 2007-02-01 2008-01-30 Твердая рецептура, которая содержит алоглиптин и пиоглитазон UA95828C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2007023594		2007-02-01

Publications (1)

Publication Number	Publication Date
UA95828C2 true UA95828C2 (ru)	2011-09-12

Family

ID=39240362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200909031A UA95828C2 (ru)	2007-02-01	2008-01-30	Твердая рецептура, которая содержит алоглиптин и пиоглитазон

Country Status (38)

Country	Link
US (1)	US8637079B2 (ru)
EP (1)	EP2107905B1 (ru)
JP (1)	JP5284968B2 (ru)
KR (1)	KR101486091B1 (ru)
CN (1)	CN101646420B (ru)
AR (1)	AR065097A1 (ru)
AT (1)	ATE488227T1 (ru)
AU (1)	AU2008211981B2 (ru)
BR (1)	BRPI0807453B8 (ru)
CA (1)	CA2677201C (ru)
CL (1)	CL2008000279A1 (ru)
CR (1)	CR10992A (ru)
CY (1)	CY1111264T1 (ru)
DE (1)	DE602008003522D1 (ru)
DK (1)	DK2107905T3 (ru)
DO (1)	DOP2009000195A (ru)
EA (1)	EA015180B1 (ru)
EC (1)	ECSP099608A (ru)
ES (1)	ES2354397T3 (ru)
GE (1)	GEP20125410B (ru)
HR (1)	HRP20110094T8 (ru)
IL (1)	IL200108A (ru)
JO (1)	JO2650B1 (ru)
MA (1)	MA31169B1 (ru)
ME (1)	ME01239B (ru)
MX (1)	MX2009008100A (ru)
MY (1)	MY147596A (ru)
NZ (1)	NZ579008A (ru)
PE (1)	PE20081663A1 (ru)
PL (1)	PL2107905T3 (ru)
PT (1)	PT2107905E (ru)
RS (1)	RS51592B (ru)
SI (1)	SI2107905T1 (ru)
TN (1)	TN2009000317A1 (ru)
TW (2)	TWI453041B (ru)
UA (1)	UA95828C2 (ru)
WO (1)	WO2008093882A1 (ru)
ZA (1)	ZA200905621B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
MX2008014024A (es)	2006-05-04	2008-11-14	Boehringer Ingelheim Int	Formas poliformas.
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
UA98799C2 (ru) *	2007-07-19	2012-06-25	Такеда Фармасьютикал Компани Лимитед	Твердый препарат, включающий алоглиптин и гидрохлорид метформина
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
KR101657960B1 (ko)	2008-08-15	2016-09-20	베링거 인겔하임 인터내셔날 게엠베하	Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체
JP2012502081A (ja)	2008-09-10	2012-01-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及び関連症状の治療のための組み合わせ治療
TW201014850A (en) *	2008-09-25	2010-04-16	Takeda Pharmaceutical	Solid pharmaceutical composition
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (es)	2009-01-29	2011-03-16	Boehringer Ingelheim Int	Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
CN102387795A (zh)	2009-02-13	2012-03-21	贝林格尔.英格海姆国际有限公司	包含dpp-4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
JP5685550B2 (ja)	2009-02-13	2015-03-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
CN107115530A (zh)	2009-11-27	2017-09-01	勃林格殷格翰国际有限公司	基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
JP2013522279A (ja)	2010-03-18	2013-06-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
US20120107398A1 (en) *	2010-05-05	2012-05-03	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions
CA2797310C (en)	2010-05-05	2020-03-31	Boehringer Ingelheim International Gmbh	Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
EP3124041A1 (en)	2010-06-24	2017-02-01	Boehringer Ingelheim International GmbH	Diabetes therapy
CN101912363A (zh) *	2010-07-29	2010-12-15	蔡海德	溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
HUE061596T2 (hu)	2011-07-15	2023-07-28	Boehringer Ingelheim Int	Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP4151218A1 (en)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103877054B (zh) *	2012-12-21	2016-05-25	北大方正集团有限公司	一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) *	2013-03-29	2013-06-19	山东罗欣药业股份有限公司	苯甲酸阿格列汀组合物片剂及其制备方法
WO2015128453A1 (en)	2014-02-28	2015-09-03	Boehringer Ingelheim International Gmbh	Medical use of a dpp-4 inhibitor
WO2016104643A1 (ja) *	2014-12-25	2016-06-30	田辺三菱製薬株式会社	糖尿病治療用固形製剤
WO2016202961A1 (en) *	2015-06-17	2016-12-22	H E X A L Aktiengesellschaft	Alogliptin formulation
CN108289849A (zh)	2015-06-26	2018-07-17	韩国联合制药株式会社	莫沙必利与雷贝拉唑的复合制剂
CN105030719B (zh) *	2015-08-20	2018-07-20	杭州成邦医药科技有限公司	一种含有阿格列汀和吡格列酮的组合物
US10155000B2 (en)	2016-06-10	2018-12-18	Boehringer Ingelheim International Gmbh	Medical use of pharmaceutical combination or composition
KR102485766B1 (ko)	2019-12-11	2023-01-09	한국유나이티드제약 주식회사	생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) *	2021-11-11	2022-11-11	乐普制药科技有限公司	一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR240698A1 (es) *	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
ATE116133T1 (de)	1990-11-27	1995-01-15	Byk Gulden Lomberg Chem Fab	Retardzubereitung für urapidil.
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
US6030641A (en) *	1997-06-03	2000-02-29	Uni Colloid Kabushiki Kaisha	Sustained release capsule and method for preparing the same
JP2931811B2 (ja)	1997-06-03	1999-08-09	ユニコロイド株式会社	徐放性カプセル
DE19725911A1 (de)	1997-06-13	1998-12-17	Roland Prof Dr Bodmeier	Zusammensetzungen, die die Wirkstofffreisetzung verzögern
AU8532798A (en)	1997-06-13	1998-12-30	Roland Bodmeier	Compounds which delay the release of active substances
AU5652199A (en)	1998-09-18	2000-04-10	Takeda Chemical Industries Ltd.	Sustained release oral preparations
JP2000154137A (ja)	1998-09-18	2000-06-06	Takeda Chem Ind Ltd	徐放性経口製剤
WO2000078333A2 (en) *	1999-06-21	2000-12-28	Eli Lilly And Company	Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
AR030920A1 (es)	1999-11-16	2003-09-03	Smithkline Beecham Plc	Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
EP1741447B1 (en)	2000-01-21	2013-09-18	Novartis AG	Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7078397B2 (en) *	2000-06-19	2006-07-18	Smithkline Beecham Corporation	Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) *	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
US6573287B2 (en)	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) *	2001-06-21	2004-02-25	Astrazeneca Ab	Formulacion farmaceutica
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) *	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
CN100367960C (zh) *	2002-07-11	2008-02-13	武田药品工业株式会社	包衣制剂的制备方法
IN192749B (ru)	2002-11-15	2004-05-15	Ranbaxy Lab Ltd
MXPA05007883A (es) *	2003-01-29	2005-09-21	Takeda Pharmaceutical	Proceso para producir una preparacion recubierta.
JP4567340B2 (ja) *	2003-01-29	2010-10-20	武田薬品工業株式会社	被覆製剤の製造方法
BRPI0414979A (pt) *	2003-10-31	2006-11-21	Takeda Pharmaceutical	preparação sólida
JP4361461B2 (ja) *	2003-10-31	2009-11-11	武田薬品工業株式会社	固形製剤
RU2766487C2 (ru)	2004-01-20	2022-03-15	Новартис Аг	Композиция и способ прямого прессования
CN102079743B (zh)	2004-03-15	2020-08-25	武田药品工业株式会社	二肽基肽酶抑制剂
CN101035522B (zh)	2004-10-25	2011-12-07	诺瓦提斯公司	Dpp-ⅳ抑制剂、ppar抗糖尿病剂和二甲双胍的组合
GT200600218A (es)	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
EP1931350B2 (en)	2005-09-14	2021-08-04	Takeda Pharmaceutical Company Limited	Administration of dipeptidyl peptidase inhibitors
TW200745079A (en)	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
JP5179363B2 (ja)	2005-12-22	2013-04-10	武田薬品工業株式会社	固形製剤
AU2006330332B2 (en) *	2005-12-28	2012-03-08	Takeda Pharmaceutical Company Limited	Therapeutic agent for diabetes

2008
- 2008-01-30 DK DK08704473.1T patent/DK2107905T3/da active
- 2008-01-30 MX MX2009008100A patent/MX2009008100A/es active IP Right Grant
- 2008-01-30 DE DE602008003522T patent/DE602008003522D1/de active Active
- 2008-01-30 ES ES08704473T patent/ES2354397T3/es active Active
- 2008-01-30 US US12/449,255 patent/US8637079B2/en active Active
- 2008-01-30 AT AT08704473T patent/ATE488227T1/de active
- 2008-01-30 EP EP08704473A patent/EP2107905B1/en active Active
- 2008-01-30 AR ARP080100381A patent/AR065097A1/es not_active Application Discontinuation
- 2008-01-30 ME MEP-2011-167A patent/ME01239B/me unknown
- 2008-01-30 AU AU2008211981A patent/AU2008211981B2/en active Active
- 2008-01-30 MY MYPI20093188A patent/MY147596A/en unknown
- 2008-01-30 ZA ZA200905621A patent/ZA200905621B/xx unknown
- 2008-01-30 SI SI200830149T patent/SI2107905T1/sl unknown
- 2008-01-30 CN CN2008800103744A patent/CN101646420B/zh active Active
- 2008-01-30 PT PT08704473T patent/PT2107905E/pt unknown
- 2008-01-30 CL CL200800279A patent/CL2008000279A1/es unknown
- 2008-01-30 GE GEAP200811445A patent/GEP20125410B/en unknown
- 2008-01-30 BR BRPI0807453A patent/BRPI0807453B8/pt active IP Right Grant
- 2008-01-30 RS RS20110080A patent/RS51592B/sr unknown
- 2008-01-30 EA EA200970726A patent/EA015180B1/ru active Protection Beyond IP Right Term
- 2008-01-30 PL PL08704473T patent/PL2107905T3/pl unknown
- 2008-01-30 TW TW097103417A patent/TWI453041B/zh active
- 2008-01-30 TW TW102128229A patent/TW201350143A/zh unknown
- 2008-01-30 CA CA2677201A patent/CA2677201C/en active Active
- 2008-01-30 HR HR20110094T patent/HRP20110094T8/xx unknown
- 2008-01-30 PE PE2008000222A patent/PE20081663A1/es active IP Right Grant
- 2008-01-30 NZ NZ579008A patent/NZ579008A/en unknown
- 2008-01-30 WO PCT/JP2008/051900 patent/WO2008093882A1/en not_active Ceased
- 2008-01-30 JP JP2009532078A patent/JP5284968B2/ja active Active
- 2008-01-30 KR KR1020097017913A patent/KR101486091B1/ko active Active
- 2008-01-30 UA UAA200909031A patent/UA95828C2/ru unknown
- 2008-02-02 JO JO200830A patent/JO2650B1/en active
2009
- 2009-07-28 IL IL200108A patent/IL200108A/en active IP Right Grant
- 2009-07-30 TN TNP2009000317A patent/TN2009000317A1/fr unknown
- 2009-07-31 DO DO2009000195A patent/DOP2009000195A/es unknown
- 2009-08-06 MA MA32148A patent/MA31169B1/fr unknown
- 2009-08-24 CR CR10992A patent/CR10992A/es unknown
- 2009-08-31 EC EC2009009608A patent/ECSP099608A/es unknown
2011
- 2011-02-09 CY CY20111100150T patent/CY1111264T1/el unknown

Also Published As

Publication number	Publication date
EP2107905A1 (en)	2009-10-14
ATE488227T1 (de)	2010-12-15
ZA200905621B (en)	2010-10-27
TW200836775A (en)	2008-09-16
IL200108A (en)	2012-02-29
DE602008003522D1 (de)	2010-12-30
JP5284968B2 (ja)	2013-09-11
BRPI0807453A2 (pt)	2014-05-20
TWI453041B (zh)	2014-09-21
CY1111264T1 (el)	2015-08-05
CN101646420A (zh)	2010-02-10
NZ579008A (en)	2012-02-24
IL200108A0 (en)	2010-04-15
CA2677201A1 (en)	2008-08-07
TN2009000317A1 (en)	2010-12-31
MX2009008100A (es)	2009-08-07
AU2008211981B2 (en)	2012-09-20
WO2008093882A1 (en)	2008-08-07
TW201350143A (zh)	2013-12-16
KR20090109115A (ko)	2009-10-19
US20100092551A1 (en)	2010-04-15
BRPI0807453B8 (pt)	2021-05-25
MA31169B1 (fr)	2010-02-01
EA200970726A1 (ru)	2010-02-26
HK1138188A1 (en)	2010-08-20
ES2354397T3 (es)	2011-03-14
EA015180B1 (ru)	2011-06-30
SI2107905T1 (sl)	2011-03-31
KR101486091B1 (ko)	2015-01-23
PT2107905E (pt)	2010-12-17
DOP2009000195A (es)	2009-08-31
PE20081663A1 (es)	2008-12-25
CN101646420B (zh)	2012-11-07
AU2008211981A1 (en)	2008-08-07
MY147596A (en)	2012-12-31
US8637079B2 (en)	2014-01-28
JO2650B1 (en)	2012-06-17
CA2677201C (en)	2015-11-17
GEP20125410B (en)	2012-02-27
PL2107905T3 (pl)	2011-04-29
HRP20110094T8 (en)	2011-07-31
EP2107905B1 (en)	2010-11-17
CR10992A (es)	2009-09-16
AR065097A1 (es)	2009-05-13
ME01239B (me)	2013-06-20
DK2107905T3 (da)	2011-01-31
ECSP099608A (es)	2009-09-29
HRP20110094T1 (hr)	2011-03-31
JP2010517937A (ja)	2010-05-27
BRPI0807453B1 (pt)	2021-01-05
CL2008000279A1 (es)	2008-08-18
RS51592B (sr)	2011-08-31

Publication	Publication Date	Title
TN2009000317A1 (en)	2010-12-31	Solid preparation comprising alogliptin and pioglitazone
MY159203A (en)	2016-12-30	Solid preparation comprising alogliptin and metformin hydrochloride
WO2008002245A8 (en)	2008-10-09	Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
NO20083863L (no)	2008-12-03	Pyrazoler som 11-beta-hsd-1
WO2007082808A3 (en)	2007-09-13	Thiazoles as 11 beta-hsd1 inhibitors
WO2008002244A3 (en)	2008-02-14	Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
WO2005075425A3 (en)	2006-12-14	Substituted bisarylurea derivatives as kinase inhibitors
WO2009032034A3 (en)	2009-04-30	Stabilized picoplatin dosage form
WO2009010416A3 (en)	2009-03-05	Inhibitors of 11b-hydroxysteroid dehydrogenase
TW200833663A (en)	2008-08-16	Therapeutic agents
WO2007060140A3 (en)	2007-09-13	Inhibitors of diacyglycerol acyltransferase (dgat)
MX374797B (es)	2025-03-06	Formulaciones farmaceuticas que contienen hidrato de propilenglicol de dapagliflozina.
BRPI0517701A (pt)	2008-10-21	uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
WO2008006795A3 (en)	2008-03-06	Indole compounds
WO2007093880A3 (en)	2007-11-01	Novel pyrone-indole derivatives and process for their preparation
IL188643A (en)	2013-05-30	Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production.
WO2007090661A3 (en)	2007-09-20	Active substance combination comprising azolylcarbinol compounds
WO2006077025A3 (en)	2006-09-08	Morpholines as 5ht2c agonists
WO2008074833A3 (en)	2008-08-28	Compounds
WO2005075471A3 (en)	2005-10-06	Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
UA91852C2 (ru)	2010-09-10	Фармацевтическая дозированная форма, которая содержит метформин и пиоглитазон как активные медикаменты
TW200639156A (en)	2006-11-16	New compounds
WO2006124413A3 (en)	2007-06-07	Methods for treating drug resistant cancer
EA200870223A1 (ru)	2009-02-27	Производные бензоизоиндола для лечения боли
TW200740424A (en)	2007-11-01	Taste masking dosage form